at://
/
app.bsky.feed.post
/
3mo3j52se7s2u
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
直接比較の第3相 #乾癬 試験において、#Zasocitinib は deucravacitinib の2.5倍超のPASI 100達成率を示し、一貫した安全性と1日1回の経口投与を確認。 www.ipharmacenter.com/post/takeda-... #ニュース #製薬 #医療 #pharma #pharmaceutical #healthcare #globalhealth #lifesciences
5h
Takeda reports that its investigational oral therapy Zasocitinib achieved markedly stronger outcomes than deucravacitinib in a head-to-head Phase 3 trial in adults with moderate to severe plaque psori...
www.ipharmacenter.com
Takeda's Zasocitinib achieved over 2.5 times the PASI 100 rate of deucravacitinib in a head‑to‑head Ph3 psoriasis trial | iPharmaCenter
